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Abstract
Broadly neutralizing HIV antibodies (bnAbs) are typically highly somatically mutated, raising doubts as to whether they can
be elicited by vaccination. We used 454 sequencing and designed a novel phylogenetic method to model lineage evolution
of the bnAbs PGT121–134 and found a positive correlation between the level of somatic hypermutation (SHM) and the
development of neutralization breadth and potency. Strikingly, putative intermediates were characterized that show
approximately half the mutation level of PGT121–134 but were still capable of neutralizing roughly 40–80% of PGT121–134
sensitive viruses in a 74-virus panel at median titers between 15- and 3-fold higher than PGT121–134. Such antibodies with
lower levels of SHM may be more amenable to elicitation through vaccination while still providing noteworthy coverage.
Binding characterization indicated a preference of inferred intermediates for native Env binding over monomeric gp120,
suggesting that the PGT121–134 lineage may have been selected for binding to native Env at some point during
maturation. Analysis of glycan-dependent neutralization for inferred intermediates identified additional adjacent glycans
that comprise the epitope and suggests changes in glycan dependency or recognition over the course of affinity maturation
for this lineage. Finally, patterns of neutralization of inferred bnAb intermediates suggest hypotheses as to how SHM may
lead to potent and broad HIV neutralization and provide important clues for immunogen design.
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A successful vaccine against HIV will likely require the
elicitation of antibody responses capable of neutralizing a majority
of global isolates. Recent work has suggested that 5–20% of HIV
chronically-infected individuals naturally develop broadly neutral-
izing responses to some degree, but how these responses emerge
and mature are unclear [1–8]. A common observation among
bnAbs is their unusually high level of somatic hypermutation
(SHM), which on average constitutes around 20% divergence
(range: 7–32%) from the putative germline nucleotide sequence
(nt) for the variable heavy chain (VHJH) region (DH-genes were left
out of these analyses because of ambiguity associated with D-gene
assignment) [2–7,9]. For example, the CD4 binding site bnAb
VRC01 is 30% and 19% mutated in its variable heavy (VHJH) and
light (VLJL) chain sequence, respectively [4,6]. The V2 quaternary
epitope-specific bnAbs PG9 and PGT145 are relatively less
mutated with 14–19% mutation frequency in VHJH and 11–
17% in VLJL, but both have unusually long CDRH3s of 30–33
amino acids [2,5]. Finally, the recently described PGT121, 128
and 135 antibodies, which bind to protein-glycan epitopes in the
variable V3 and V4 regions and demonstrate the highest potency
yet observed against a broad panel of HIV isolates, are 17–23%
divergent in VHJH and 11–28% divergent in VLJL [5,8,10]. Of
note, a number of the bnAbs also have insertions or deletions
(indels) in their variable regions and recent crystal structures have
identified indels as critical for protein or glycan contacts on HIV
Env [4,7,11]. Interestingly, gp120-reactive antibodies that show no
or low neutralizing activity from chronically HIV-infected
individuals demonstrate a relatively high but lesser degree of
SHM than bnAbs, in the range of 9–12% in VHJH [12,13].
In contrast to HIV bnAbs, antibodies from vaccination in
general have an average nt mutation frequency of 6% (range: 1–
30%) in the VH, which has cast doubts on the likelihood of eliciting
bnAbs through vaccination [14–21]. We note that while these
previous studies are caveated by insufficient sampling of antibody
responses, due in large part to technological limitations, they
nonetheless provide an approximation of the large discrepancy in
mutation frequency between antibodies typically elicited through
vaccination and HIV bnAbs. Currently, no immunogen has
reliably elicited significant levels of HIV bnAbs to circulating
viruses. Part of this failure might be due to inadequate immunogen
design, but assuming high mutation levels play a significant role in
enabling neutralizing breadth and potency, it is also possible that
current immunization approaches are failing because of an
inability to elicit sufficient levels of SHM. In one report,
immunization with monomeric gp120 in humans was only capable
of eliciting antibodies with an average mutation frequency of ,6%
[18]. Similarly, Env trimer immunization in rhesus macaques
produced an average VH mutation frequency of 10% [19]. A
further complexity is the association of broad neutralization with
indels, sometimes relatively long, in some bnAbs as described
above. The frequency of indels is associated with the extent of
SHM; typical immunization procedures that produce moderate
levels of SHM produce a relatively low number of indels and the
frequency of longer indels is particularly uncommon. The
frequency of indels among bnAbs may therefore present another
obstacle for their elicitation by vaccination [22].
Given the large gap between the average mutation frequency of
antibodies elicited by vaccination and bnAbs, it will prove helpful
to identify broad and potent neutralizing antibodies with lower
mutation frequencies as viable candidates for bnAb elicitation by
vaccination. The levels of SHM that are necessary for broad and
potent neutralization is poorly defined. Much work has been done
to demonstrate that complete reversion of VHDHJH and VLJL
sequences of HIV bnAbs to the corresponding germline sequences
generally abrogates neutralizing and binding activity, which
suggests that some degree of SHM plays an important role in
the development of neutralizing breadth and potency [23–26].
More recent studies involving reversion of all framework (FR)
mutations was shown to affect binding and neutralization for
bnAbs but not for non-broadly neutralizing antibodies, suggesting
that high levels of SHM are necessary for neutralization breadth
and potency [9]. Similarly, a 12 amino acid reversion in the VH of
VRC01 was sufficient to negatively affect neutralization breadth
[4]. In a different study, characterization of inferred intermediates
from longitudinal samples identified less-mutated CD4bs bnAb
intermediates, though these putative precursors were greatly limited
in neutralization breadth and potency [27]. Based on longitudinal
serum neutralization data, it appears that neutralization breadth
generally requires up to 4 years post-infection in order to develop,
further supporting the idea that antibodies are going though many
rounds of maturation before gaining breadth of neutralization
[8,10]. Longitudinal analysis of a SHIV-infected macaque, howev-
er,demonstrated the rapid emergenceofneutralization breadth and
potency against the N332 epitope suggesting potential differences in
the dependence on SHM levels [8,28,29].
Previous work has attempted to map the maturation process
from germline to affinity matured antibody for a group of highly
broad and potent CD4 binding-site antibodies using deep
sequencing analysis [6]. However, less mutated antibody interme-
diates identified by traditional phylogeny in that study did not
demonstrate neutralization activity. To identify less-mutated
intermediates with broad and potent neutralization, we used deep
sequencing to study the development of neutralization breadth in
the donor from whom bnAbs PGT121–123 were isolated. These
antibodies are among the most potent bnAbs described to date and
provide protection in macaques at relatively low serum levels [30].
Thus, the PGT121–123 family of antibodies are promising vaccine
leads because their high potency suggests that even modest titers of
antibody in the serum might be capable of contributing to
protection. Ideally, the evolution of a bnAb response would be
followed in longitudinal samples as infection progressed. However,
since such samples were not available for this donor, we used 454
Author Summary
A majority of the over 30 million HIV-1 infected individuals
worldwide live in poorly resourced areas where multiple
boost strategies, which are likely needed to generate
highly mutated antibodies, present formidable logistical
challenges. Accordingly, developing new vaccination
strategies that are capable of generating highly mutated
antibodies should be an active area of research. Another
approach, that is not mutually exclusive, is to identify new
bnAbs that are both broad and potent in neutralization,
but are much less mutated than the bnAbs that currently
exist. Here, we have identified bnAbs that are approxi-
mately half the mutation frequency of known bnAbs, but
maintain high potency and moderate breadth. These less
mutated bnAbs offer an important advantage in that they
would likely be easier to induce through vaccination than
more mutated antibodies. By characterizing these putative
intermediates, we can also better estimate how affinity
maturation proceeded to result in an antibody with broad
and potent neutralization activity and offer more focused
strategies for designing immunogens capable of eliciting
these less mutated bnAbs.
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and model the lineage evolution of the PGT121–123 family. We
performed this analysis on PBMCs drawn at the same time point
as that previously used to isolate PGT121–123 [5]. To analyze the
resulting set of sequences, we developed a novel method called
ImmuniTree, which is an alternative approach to conventional
phylogenetic analyses and is designed specifically to model
antibody SHM. Our results suggest that the PGT121 family of
antibodies is capable of demonstrating appreciable breadth and
high potency at relatively modest levels of SHM.
Results
ImmuniTree models SHM of the PGT121–123 lineage
To produce libraries for 454 sequencing, gene-specific primers
were used on 54,000 sorted IgG+ memory B cells to amplify
..IGHV4-59 and IGLV3-21 gene families from which the
PGT121–124 and PGT133–134 antibodies were derived [5].
PGT124, PGT133, and PGT134 are somatic variants of
PGT121–123 monoclonal antibodies (mAbs) that were recently
isolated through direct functional screening and by antigen-based
cell sorting (Figure 1). These libraries were then submitted to 454
sequencing to yield a total of 376,114 heavy-chain and 530,197
light-chain reads.
To define unique clones, the V and J gene for each read was
determined along with its percent mutation from the correspond-
ing germline sequence. We then analyzed the clustering quality
using multiple values for the cutoff range. The distribution of
cophenetic distances in the hierarchical clustering linkage tree
showed that a cutoff of 4–5 ‘‘edits’’ was optimal, because at that
distance, the distribution had a qualitative change most likely
associated with sequencing error. Given the average length of the
Figure 1. Mutation summary of selected heavy and light chain clones. Mutation frequency was calculated over the V-gene and J-gene as
nucleotides or amino acids differing from the putative germline sequence for (A) heavy chain sequences and (B) light chain sequences. The CDR3
regions and insertions and deletions were excluded from the analysis. CDR3 lengths were determined according to the IMGT definition. Analyses
were performed with the SciPy stack [53] and figures were generated using matplotlib [54] and graphviz [55].
doi:10.1371/journal.ppat.1003754.g001
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determining region 3 (CDR3), 4–5 edits corresponds to a 90%
identity using USEARCH’s iddef 1 option [31]. Target PGT
antibody sequences were manually selected for further analysis as
follows. Each read was scored on its identity to a PGT antibody
and on its mutation level from the IMGT reference germline
sequence. The vast majority of reads formed several large, low-
identity clusters in a divergence-mutation scatter plot; in some
cases, there existed small clusters of high-identity reads separate
from the large clusters (Figure 2A–B and Figure S1, S2). These
small clusters were manually extracted and carried forward for
phylogeny. This approach identified a total of 97 heavy-chain and
530 light-chain sequences as PGT121–134 variants. The greater
number of light chain variants is likely due partly to more raw
reads from the sequencing run and partly to library preparation,
which has also been observed by other deep sequencing studies of
HIV antibody repertoires [6,32]. Indeed, the primers we used to
amplify the heavy chains were not as specific as the light chain
primers and so there may have been less enrichment for heavy
chain sequences. Sequence variants were then used to model the
history of the PGT121–134 antibody lineage so as to experimen-
tally characterize early less-mutated variants. We designed a new
Bayesian phylogeny algorithm, ImmuniTree, to model the SHM
of this lineage (Text S1).
Existing approaches to phylogeny were suboptimal for our
experiment because of two principal issues. Firstly, existing
Figure 3. Selected heavy and light chain clones were paired and tested for neutralization breadth and potency on a cross-clade 6-
virus panel. Neutralization breadth and potency summary of all the paired clones. The clones are arranged from least (bottom-left) to most (top-
right) mutated with heavy chain listed on the left and light chain listed across the bottom. Boxes are colored according to neutralization score, which
is defined as mean(log10(10/IC50)); black boxes represent pairs whose neutralization scores were not determined.
doi:10.1371/journal.ppat.1003754.g003
Figure 2. PGT121–123 variants identified by deep sequencing were used to build phylogenetic trees using ImmuniTree. (A)A n
example identity (y-axis) and mutation (x-axis) plot for PGT121 used to identify PGT121-variants for heavy chain and for (B) light chain; each color
represents a unique clone. (C) Heavy chain and (D) light chain SHM phylogenies inferred by the ImmuniTree algorithm. Nodes that were inferred by
the algorithm are represented as small circles. Nodes representing observed sequences are depicted as larger circles; node size is proportional to the
number of reads assigned to that node. The trees are colored based on level of mutation from germline. Previously isolated affinity matured mAbs
are labeled (e.g. PGT122) and nodes selected for synthesis and characterization are labeled blue.
doi:10.1371/journal.ppat.1003754.g002
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leading to excessive branching in the phylogeny and difficulties in
interpretation. ImmuniTree addresses this obstacle by taking
advantage of the distinctly different nucleotide transition charac-
teristics between clonal SHM and 454 sequencing errors.
Secondly, traditional phylogeny algorithms do not explicitly model
whether or not to generate an internal node. Instead, these
algorithms either always infer an internal unobserved intermediate
(e.g. neighbor joining), or never do so (e.g. minimal spanning
trees). This poor representation inaccurately models reality, where
noisy yet highly clonal data are observed from only a subset of
leaves and internal clones.
Though emerging methods address only one or neither of these
issues [33], ImmuniTree addresses both explicitly (Text S1). For
each antibody clone, the algorithm models SHM as a birth-death
model, where reads are generated from clonal populations using a
known sequencing error model. The algorithm jointly models
sequencing error alongside somatic mutation and collapses reads
that differ due to sequencing error. The approach reduces
inference variance and facilitates human interpretation when
choosing sequences for the subsequent evaluation of binding and
neutralization.
The ImmuniTree algorithm relies on a probabilistic model that
describes both the expansion process of a clone and the sequencing
process. It iteratively explores this probabilistic space using the
Markov chain Monte Carlo framework [34], producing a new
hypothetical tree in each iteration, aimed at describing how the
data were generated. In the hypothesized tree, each node is
associated with one sequence, and the reads are associated with
the nodes of the tree. The disagreements between the sequence of
a node and its parent represent new hypermutations. The
disagreements between a read and the sequence of its node
represent sequencing errors. The mechanics of the algorithm
guide the search to high-likelihood areas of the probabilistic space.
During each iteration the tree is constantly manipulated,
intermediate nodes are stochastically added and deleted, and if
such nodes contribute to a tree that better explains the data, they
are likely to stay. Then, the DNA sequences of all the nodes in the
hypothesized tree, including intermediates, are jointly updated by
an exact inference algorithm [35]. At the end of the search, the
algorithm returns the tree with the highest likelihood.
Given the tree topology, and the association of reads to nodes in
the tree (the ‘‘evidence’’), we use belief propagation algorithm to
infer the sequences of all the nodes, including intermediate nodes.
The belief-propagation algorithm is a message-passing algorithms,
a generalization of the backward-forward algorithm for hidden
Markov models (HMMs), which computes the set of sequences
that yield the highest likelihood according to the mutation model.
Each node in the tree receives ‘‘messages’’ from its children
stating their best estimate for its sequence. Each child’s estimate is
based on the evidence in its subtree, taking into account the
mutation model. Those messages are integrated with the evidence
at the node itself into a new message that is sent to its own parent,
estimating the parent’s sequence. Once the root of the tree
received all the messages from its children, it sends to each of its
children its best estimate, now fully informed, for their sequence.
This process is repeated until all the nodes in the tree are
instantiated with their optimal sequences, given to them by their
parent.
When applied to the PGT121–134 variants, ImmuniTree
generated trees for heavy and light chain sequences with a total
of 37 nodes (named 1H through 37H) and 120 nodes (named 1L
through 120L), respectively (Figure 2C–D). Within these two trees,
13 internal nodes in the heavy chain tree and 28 internal nodes of
Figure 4. Selected heavy and light chain clones were paired
and tested for neutralization breadth and potency on a cross-
clade 6-virus panel. (A) Heavy and light chain nodes leading to mAb
PGT121 and (B) PGT124 were paired and tested on a 74-virus panel of
PGT121- or PGT124-sensitive viruses. Boxes are colored by IC50 values
(mg/ml) of each isolate neutralized.
doi:10.1371/journal.ppat.1003754.g004
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PLOS Pathogens | www.plospathogens.org 6 November 2013 | Volume 9 | Issue 11 | e1003754Figure 5. Higher levels of somatic hypermutation correlates with greater neutralization breadth and potency. (A) Summary of
neutralization data in Figure 4A–B by each clade neutralized. Listed in colored boxes are percentage values. (B) Overall mutation frequencies of mAb
combinations, which were calculated by overall number of nucleotide mutations in both heavy and light chains divided by combined heavy and light
chain lengths. The mutation frequency of each heavy and light chain was calculated over both V- and J-genes.
doi:10.1371/journal.ppat.1003754.g005
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direct sequencing data (Figure 2C–D). As expected, trees built
without correcting for sequencing error resulted in a larger
number of nodes and branches, which confounds lineage analysis
(Figure S3). Overall, compared to the inferred internal nodes, the
observed nodes in both heavy and light chain trees were relatively
highly mutated with an average divergence from germline of 18%
for VH and 24% for VL. The observation that only highly mutated
sequences were found suggests that early precursors might be
absent in the B cell memory compartment or are present at very
low levels, possibly because the donor blood samples were
obtained several years into the infection. Indeed, this observation
is consistent with other antibody lineage studies for which inferred
intermediates were calculated because less-mutated sequences
were absent or were present at very low frequencies in the
sequencing dataset in both late time point samples and even in
early blood draws from longitudinal studies [6,27,32]. We were
particularly interested in whether these less-mutated inferred
precursors could also exhibit broad neutralization.
Neutralization activity positively correlates with degree
of SHM
To see if observed and inferred sequences were capable of
generating functional antibodies, we paired heavy and light chain
sequences from nodes of varying mutation levels and measured
neutralization activity on a cross-clade 6-virus panel to evaluate
neutralization breadth and potency (Figure 3) [36]. As shown in a
recent study, the PGT121 family of antibodies retained full function
onlywhenheavyand lightchainswithinthelineagewere pairedand
were not functional or suffered a great reduction in neutralization
and binding when paired with heavy or light chains from other
N332-specific antibodies [37]. Moreover, the structural similarity
between somatic variants suggests that heavy and light combina-
tions within the lineage should give rise to antibodies capable of
binding and/or neutralization [38,39]. Indeed, the variants and
putative intermediates selected in this study share many of the
amino acid motifs characteristic of this family of antibodies and are
therefore presumed to fold into similar antibody structures. Thus,
while the heavy and light chain pairs presented here may not
recapitulate natural in vivo pairing, the differences in SHM levels
between chimeras can still offer insight into the contribution of
SHM to the antibody lineage’s neutralization breadth and potency.
The mutation levels of the selected clones in comparison to
known heavy and light chain pairs from this donor are listed in
Figure 1. We selected the intermediates based only on mutation
frequency. For example, we chose the least mutated nodes 3H for
heavy chain and 3L for light chain to determine if neutralization
activity was achievable at these levels of SHM. Additionally, we
chose nodes that followed consecutively in SHM levels (e.g. 9H to
10H to 13H for heavy chain and 84L to 87L to 109L for light
chain) to determine if the level of SHM correlates with
neutralization breadth and/or potency. Surprisingly, pairing of
the least mutated nodes (3H+3L) resulted in a variant that
demonstrated notable neutralization activity (Figure 3). Also,
antibody clones comprising heavy and/or light chain sequences
that are more divergent from germline consistently demonstrated
greater neutralization potency and/or wider breadth on the 6-
virus panel (Figure 3 and Figure S4). Some combinations from
observed sequences, however, were unable to demonstrate
neutralizing activity, which could be due to either incorrect chain
pairing or the accumulation of deleterious mutations during SHM
that rendered them no longer functional.
To investigate further, we chose to characterize putative
intermediates for the affinity matured PGT121 and PGT124
antibodies, which lie on different branches of the evolutionary tree
and have slightly different neutralization profiles (Figure 2C–D
and Figure S5, S6). As an inferred precursor to both antibodies, we
chose the least mutated nodes 3H from the heavy chain tree and
3L from the light chain tree. To investigate intermediate levels of
SHM, we chose 9H as a heavy chain precursor of PGT121–123
and 32H as a precursor of PGT124. Finally, we also tested pairing
with node 87L from the light chain tree as it demonstrated very
high neutralization breadth and potency when paired with various
heavy chains.
With a mutation frequency of 5% in VHJH and 9% in VLJL
(overall nt mutation frequency of 6%), the antibody 3H+3L
nevertheless neutralized 46% of a broader panel of 74 viruses
sensitive to PGT121/PGT124 with a median IC50 only 24- and
14-fold higher than PGT121 and PGT124, respectively
(Figure 4A–B, Figure 5A and Figure S7, S8). With a few
additional nucleotide mutations in the heavy chain (11% in VHJH,
overall nt mutation frequency of 10%), the 32H+3L pair
neutralized 80% of viruses that are sensitive to PGT124 with
only 1.5-fold higher median IC50 than PGT124. The inferred
intermediate for PGT121, 9H+3L, is 12% mutated in VHJH (also
10% nt mutation frequency overall), but demonstrated less
breadth and potency neutralizing 62% of PGT121-sensitive
viruses with a 12-fold higher median IC50 than PGT121. Overall,
the results confirm that, while SHM does enhance neutralization
breadth and potency for this family of antibodies (Figure 4A–B),
we are still able to observe relatively high levels of broad
neutralization activity with substantially lower levels of SHM than
found for the most affinity-matured antibodies.
To better evaluate the neutralization activity of the antibodies of
intermediate divergence, 3H+3L and 32H+3L were tested on a
103 cross-clade virus panel in comparison with b12 and PGT121
(Figure S9, S10). b12 was one of the first CD4bs bNAbs isolated
and demonstrates moderate neutralization breadth compared to
more recently isolated bNAbs [3,5]. The results show that the least
mutated pair 3H+3L is 6% less mutated than b12, but
demonstrated equivalent breadth (26%) and its median IC50 was
still 3-fold more potent than b12 and 15-fold less potent than
PGT121. The pair 32H+3L, meanwhile, was capable of neutral-
izing 48% of viruses on this panel and its median IC50 is 15-fold
more potent than b12 and only 3-fold less potent than PGT121.
PGT121 was capable of neutralizing 58% of viruses on this panel.
Thus, while SHM does enhance neutralization breadth and
potency for this family of antibodies, we are still able to observe
relatively high levels of neutralization activity with substantially
lower levels of SHM than the fully matured clones.
Residues arising through SHM are important for
neutralization at different stages of antibody maturation
In order to determine if residues in the variable region are a
result of SHM or are due to polymorphisms in the donor, genomic
DNA from the PGT121–123 donor was extracted and V and J
genes from both heavy and the light chains were amplified and
Sanger sequenced (Figure S11). Based on the results, there are no
unique polymorphisms in the donor that distinguish the germline
sequence from those reference sequences found in the IMGT
database. Additionally, the sequence results indicate that the
deletion in FR1 and the insertion in FR3 of the light chain, which
are present in the PGT121–134 mAbs, were features that
developed following VDJ or VJ recombination.
We next determined how individual mutations at different
stages of antibody maturation enabled greater neutralization
breadth or potency to gain insight into the most critical steps of
SHM for this family of antibodies. For the antibody 3H+3L, single
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PLOS Pathogens | www.plospathogens.org 8 November 2013 | Volume 9 | Issue 11 | e1003754Figure 6. Role of somatic hypermutation in neutralization and antibody structure. (A) Residues from heavy chain intermediates and light
chain intermediates were reverted to germline while indel and CDR3 residues were individually mutated to alanines and tested on a cross-clade virus
panel. Highlighted in blue are residues that were reverted to germline. Highlighted in orange are residues reverted between intermediates. Filled red
dots represent residues reversions that resulted in significant loss of neutralization as single reversions. Empty red dots represent residue reversions
that resulted in significant loss of neutralization as pairwise reversions. Reported fold changes in IC50 are shown in Figure S12. (B) Reported fold
changes in IC50 for residues reverted to germline in putative intermediate 3H+3L. (C) Residues that were found to be critical for neutralization in (B)
were mapped on a putative PGT121 germline crystal structure. Global structural shifts were observed between germline (gray) and PGT121 (colored).
Arrows indicate shifts of CDR loops. (D)1 1A ˚ shift of R
L94 in the CDRL3, which was identified to be important for neutralization activity. (E) Salt bridge
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H100 in the CDRH3 and D
L67 in the FRL3 insertion that contributes to structural shifts. (F) Effect of N51D mutation in CDRL2. N
L51 is highly
conserved among all antibody variants and substitution completely abrogates neutralization. The introduction of two hydrogen bonds between the
side chain of N
L51 and backbone atoms might facilitate a helix to loop change in CDRL1. (G) A H34Q substitution in CDRL1 contributes to stabilizing
the proximal positions of CDRL1 and CDRL2.
doi:10.1371/journal.ppat.1003754.g006
Figure 7. Neutralization activity of PGT122–133 mAbs without the FRL3 insertion and restoring the N-terminus deletion. The three
amino acid insertion in FR3 of the light chain of (A) PGT122, (B) PGT123, (C) PGT124, and (D) PGT133 was removed and paired with the
corresponding heavy chains and tested for neutralization activity on a 6-virus panel. Solid lines represent wild-type antibodies with the insertion and
dashed lines represent the antibodies without the FR3 insertion. (E) The 7 amino acid N-terminus sequence of IGHV4-59 germline was placed back
into the N-terminus of PGT121 and tested for neutralization breadth and potency on a cross-clade 6 virus panel. Solid lines represent WT PGT121
(with N-terminal deletion) and dashed lines represent PGT121 with the N-terminus restored.
doi:10.1371/journal.ppat.1003754.g007
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germline residue and residues comprising a framework light chain
3 (FRL3) insertion and CDR3 regions were individually substi-
tuted by alanine (Figure 6A–G). The parent 3H+3L mAb and
mAb variants were then tested for neutralization on a 6-virus panel
and the fold changes in IC50 are reported in Figure 6B and Figure
S12. For the heavy chain of antibody 3H+3L, most of the
neutralization activity for the majority of isolates is apparently
mediated through the CDRH3; simultaneous reversion of all the
heavy chain residues of 3H to germline, except for the CDRH3,
resulted in loss of neutralization or reduced potency for only 20%
of isolates (Figure S13). For the light chain of antibody 3H+3L,
residues critical for neutralization activity were found in both
framework and CDR regions, although these residues become less
critical when paired with more mature heavy chains (Figure S14).
Crystallographic studies of a putative PGT121 germline Fab,
which is similar (0.4 A ˚ core RMSD) to a previously reported
crystal structure of another PGT121 putative germline antibody,
suggested that the mutations from germline not only involved
likely antigen contact residues, but also involved structural
rearrangements in the heavy and, most notably, light chains as a
result of somatic mutation in CDR and framework regions
(Figure 6C–G, Figure S14, and Table S1) [39].
Having identified the residues mutated from germline that are
most crucial to neutralization by antibody 3H+3L, we were
interested in determining those that were most important to the
increased breadth of antibodies 32H+3L and 3H+87L as
compared to 3H+3L. Accordingly, the more mutated intermediate
heavy chain 32H was reverted to the less mutated 3H heavy chain,
paired with light chain 3L, and tested for neutralization breadth. A
similar approach was taken for reversion of light chain 87L to 3L,
paired with heavy chain 3H. Surprisingly, single amino acid
changes did not show demonstrable effects on neutralization IC50
for the 32H reversion or for the 87L reversion (Figure S15).
Strikingly, only variants for which at least two amino acids were
reverted did we see a large increase in IC50 between parent and
variant mAb in an isolate-specific manner. Such a pattern may
present extra challenges to the guided evolution of an antibody
response through vaccination.
To gain further insight into the effects of the insertion and
deletions on neutralization activity, we tested neutralization
breadth and potency of the PGT122–133 antibodies without the
FRL3 insertion and restoring the framework light chain 1 (FRL1)
deletion on a cross-clade 6 -virus panel. Upon removal of the
FRL3 insertion, we observed a partial loss of neutralization in an
isolate-specific manner that varied somewhat among the somatic
variants of the lineage (Figure 7A–D). The isolate 92BR020, for
example, became resistant to neutralization by PGT123 lacking
the FRL3 insertion, but was still sensitive to the corresponding
PGT122, PGT124, and PGT133 variants. Meanwhile, the isolate
IAVI C22 became resistant to PGT122 lacking the FRL3
insertion, but remained sensitive to PGT123, PGT124, and
PGT133 variants. Notably, the isolate 92RW020 remained
sensitive to all the antibodies in the absence of the FRL3 insertion.
These results suggest that the FRL3 insertion is beneficial but not
absolutely crucial for neutralization breadth and that the antibody
maturation process may have proceeded some way before the
insertion occurred. These results also argue that, if an immunogen
is capable of eliciting this lineage of antibodies without the FRL3
insertion, neutralization breadth may be achieved through the
complementary neutralization profiles of somatic variants. Finally,
we were unable to find large effects on neutralization breadth or
potency upon restoration of the 7-amino acid N-terminus deletion
in FRL1 suggesting that this feature is not crucial for bnAb activity
(Figure 7E).
Intermediate antibody binds cell surface Env more
effectively than monomeric gp120 and shows greater
dependence on recognition of multiple glycans than
mature PG121
Many research groups have generated germline derivatives or
close equivalents (unmutated germline ancestors) of known bnAbs,
but these constructs do not bind most recombinant gp120s or
neutralize most virus strains [23,25,26,40]. Indeed, the putative
germline of PGT121 was unable to bind gp120 (Figure 8A–B).
However, the intermediate 3H+3L antibody did bind weakly to
monomeric gp120 from multiple isolates. Most notably, the
3H+3L antibody bound to monomeric gp120 with notably lower
apparent affinity than to trimeric cell surface Env in contrast to
Figure 8. Putative germline of PGT121 does not bind
monomeric gp120 or cell surface Env. (A) PGT121germline does
not bind recombinant gp120 (92BR020). Recombinant gp120s were
produced in 293F cells and purified by lectin column before use in
ELISA binding assays. ELISA values are reported in optical density at
405 nm (OD405). (B) PGT121germline does not cell surface Env
(92BR020). Cell surface Env was produced by transfecting pseudovirus
in 293T cells and binding was measured by flow cytometry (reported in
mean fluorescence intensity or MFI).
doi:10.1371/journal.ppat.1003754.g008
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PLOS Pathogens | www.plospathogens.org 11 November 2013 | Volume 9 | Issue 11 | e1003754Figure 9. Inferred intermediate antibodies preferentially bind native Env relative to monomeric gp120. mAbs 3H+3L (blue) and PGT121
(red) were tested for binding by ELISA to monomeric gp120, which was extracted from lysed virus supernatants: (A) 92BR020, (C) 92RW020, (E) JR-FL
E168K/N192A, (G) IAVI C22. Antibodies were also tested for cell surface Env binding by flow cytometry: (B) 92BR020, (D) 92RW020, (F) JR-FL E168K/
N192A, (H) IAVI C22. mAb 2G12 was included as a control (gray). ELISA values are reported as optical density at 405 nm (OD405) and flow cytometry
values are reported as mean fluorescence intensity (MFI).
doi:10.1371/journal.ppat.1003754.g009
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monomeric gp120 and trimeric Env (Figure 9A–B and Figure
S16). We confirmed by competition assays that, despite these
binding differences, antibodies 3H+3L and PGT121 do share
overlapping epitopes (Figure 10A). To determine if the preference
of antibody 3H+3L for trimeric Env was due to avidity effects, we
generated Fab fragments and tested neutralization activity and
binding by flow cytometry. The results demonstrate that 3H+3L
loses neutralization potency as an Fab compared to IgG, despite
little difference in apparent affinity for cell surface trimer between
Fab and IgG (Figure 10B–C). Conversely, PGT121 maintains
neutralization potency as a Fab. These results suggest that the
early intermediate antibodies may be crosslinking between Env on
virions in order to achieve neutralization [7], but the lineage
becomes less dependent on crosslinking following affinity matura-
tion. Overall, these results indicate that the PGT121–134 antibody
lineage may have been selected for native Env binding at some
point during maturation, possibly on whole virions.
Previous work identified only the N332 glycan as critical for
PGT121 neutralization and binding [5,41]. However, because all
Figure 10. Antibody 3H+3L likely crosslinks between trimers. (A)3 H +3L binds an epitope overlapping with those of PGT121, PGT128, and
2G12 as shown by competition of biotinylated antibody 3H+3L with an antibody panel. Binding assays were performed by flow cytometry on JR-
FLDCT isolate transfected in 293T cells. (B) IgG and Fab fragments were tested for binding on JR-FLDCT isolate expressed on transfected 293T cells
and no substantial differences in avidity were observed. Solid lines represent IgG and dashed lines represent Fab fragments. (C) Purified IgGs of
3H+3L and PGT121 were digested into Fab fragments using Lys-C, purified, and tested for neutralization on a cross-clade panel. Loss of neutralization
was found for 3H+3L Fab, but not for PGT121 Fab. Reported values are IC50 ratios of Fab compared to IgG using the equation: (IC50 Fab):(IC50 IgG).
doi:10.1371/journal.ppat.1003754.g010
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binding of adjacent glycans, we tested our putative precursors for
involvement of other glycans in neutralization [5,7,42–44].
Reduced neutralization on N301A viruses and complete loss of
neutralization on N332A viruses was found for 3H+3L, 32H+3L,
and 9H+3L mAbs (Figure 11A–C). For PGT121, we observed no
effects for N301A viruses, a substantial loss of neutralization for
N332A viruses, and an even greater loss of neutralization for
N332A+N301A mutant viruses (Figure 11D–F). Overall, the
results suggest that early antibodies of the PGT121–123 lineage
are dependent on both N301 and N332 glycans and that the
dependency on the N301 glycan is reduced upon maturation.
Figure 11. Neutralization assays on JR-FL glycan mutants indicate binding of inferred intermediate antibodies to both N301 and
N332 on HIV-1 Env. (A) Neutralization curves of inferred intermediate antibodies on wild-type JR-FL virus (B) JR-FL N301A mutant virus, and (C) JR-
FL N332A mutant virus. (D) Neutralization curves of 3H+3L and (E) PGT121 on wild-type JR-FL virus compared to single and double glycan mutant
viruses. (F) Neutralization curves of PGT121 on wild-type 92BR020 virus compared to single and double glycan mutant viruses.
doi:10.1371/journal.ppat.1003754.g011
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The conclusions described here can help guide immunogen
designtoelicitPGT121-likeantibodies.Specifically,thepresentation
of native Env instead of monomeric gp120 in germinal centers
appears to be important for the maturation of this family of
antibodies. This preference for native Env over monomeric gp120
may be due to avidity effects or to the presentation of epitope
residues onnative Envthat are not fullyrecapitulated onmonomeric
gp120. Additionally, we observed an evolution in the dependency of
glycan binding between putative intermediates and fully mature
antibody. As conventional protein-glycan interactions are usually in
the micromolar range, the avidity offered by binding to multiple
glycans may be an important factor in triggering glycan-dependent
bnAb lineages. By comparing the differences in glycan contact
residues between putative precursor and affinity-matured antibody,
it may be possible to rationally target residues for maturation in
order to achieve greater neutralization breadth.
Compared to less-mutated bnAbs that target the CD4 binding
site [27] the less-mutated intermediates presented here are notably
broader and more potent suggesting potentially important
differences between the CD4 binding site and the N332 region
as vaccine targets that may give some advantage to the latter
region. One possible explanation is that antibodies targeting the
CD4bs may require more SHM in order to fold into specific
conformations that enable binding into the CD4bs pocket. The
epitope that PGT121 binds to, on the other hand, may be more
exposed and may accommodate different antibody binding
angles [7,11,37,38]. Thus, the PGT121 lineage may not
necessarily require extensive levels of SHM in order to bind its
epitope. It would likely be informative to perform similar
analyses for other known bnAbs in order to better define the
minimal amount of mutations necessary to achieve neutralization
breadth and potency for different bnAbs.
Despite the lower levels of SHM associated with PGT121-like,
more VRC01-like antibodies than PGT121-like bnAbs have been
isolated from various donors. This apparent discrepancy may be
due to the fact that many B cell selection studies have used a bait
(RSC3) engineered for isolating VRC01-like antibodies . Addi-
tionally, there are many donors in various cohorts who show N332
serum reactivity whose antibodies have not yet been isolated and
thus new PGT121-like antibodies may be forthcoming. Finally,
antibodies targeting the N332 epitope appear to derive from
several VHDHJH and VLJL combinations, while VRC01-class
antibodies utilize only a single VH germline gene, the VH1-2 gene.
Thus, given the greater diversity of antibody responses targeting
the N332 epitope, the probability of identifying an exact or highly
similar PGT121 response from other infected donors may be low.
Importantly, as shown here, deep sequencing and phylogeny
with ImmuniTree has the potential to identify intermediate
antibodies that may not be as broadly neutralizing as some
individual affinity-matured Abs, but have considerably lower levels
of SHM. In this regard, considerable neutralization breadth may
be achieved by eliciting less-mutated antibodies with complemen-
tary neutralization profiles, probably targeting a range of epitopes.
Such an approach may circumvent the need for long-term prime/
boost strategies, which are likely required to elicit high levels of
SHM and suggests that, given the right immunogens, more
conventional vaccination strategies than have been contemplated
may be sufficient for an HIV vaccine.
Strikingly, it appears that higher levels of SHM concurrently
enhance neutralization breadth and increase potency against the
majority of isolates recognized by putative precursors (Figure 4A–B
and Figure S7, S8). These observations are consistent with the
hypothesis that SHM results in some antibodies becoming both very
broad and potent by ‘‘homing in’’ on a conserved site of
vulnerability (‘‘sweet spot’’) from a response that initially recognizes
a somewhat different footprint on the virus Env. One hypothesis
suggests that Env escape variants drive maturation to avoid variable
residues and/or glycans adjacent to the most conserved residues by
directing contacts to converge on the smallest and most conserved
binding site on Env (compare ref. [45]). An alternative hypothesis
suggeststhat the antibody maturesto avoidvariableresiduesand/or
glycans without substantially changing the size of its footprint but by
refining its angle of approach (compare ref. [46]). By either of these
mechanisms, antibody selection can occur on the basis of affinity for
diverse isolates with a concomitant increase in neutralization
breadth and potency (Figure 4A–B and Figure S17). Indeed,
calculations of an antigen-antibody interaction model are consistent
with the idea that bnAbs are characterized as antibodies that form a
small number of stronger interactions with conserved residues
compared to antibodies that are able to make many contacts with
many variable residues (Figure S18). Further dynamic modeling of
antibody SHM in response to Env escape in concert with targeted
immunization studies will help to design vaccines and vaccine
strategies that hone antibody responses onto the the PGT121
epitope.
Materials and Methods
Ethics statement
Peripheral blood mononuclear cells (PBMCs) were obtained
from donor 17, an HIV-1 infected donor from the IAVI Protocol
G cohort [36]. All human samples were collected with written
informed consent under clinical protocols approved by the
Republic of Rwanda National Ethics Committee, the Emory
University Institutional Review Board, the University of Zambia
Research Ethics Committee, the Charing Cross Research Ethics
Committee, the UVRI Science and Ethics Committee, the
University of New South Wales Research Ethics Committee. St.
Vincent’s Hospital and Eastern Sydney Area Health Service,
Kenyatta National Hospital Ethics and Research Committee,
University of Cape Town Research Ethics Committee, the
International Institutional Review Board, the Mahidol University
Ethics Committee, the Walter Reed Army Institute of Research
(WRAIR) Institutional Review Board, and the Ivory Coast Comite ´
National d’Ethique des Sciences de la Vie et de la Sante ´
(CNESVS).
454 sequencing library preparation
Reverse transcription was performed with 10 mL total RNA and
2 mL RT primer mix (50 mM oligo-dT and 25 mM random
hexamer). The mixture was heated at 95uC for 1 min, 65uC for
5 min, then cooled on ice for 1 min. For each reaction, a mix was
prepared with 4 mL5 6FS buffer, 1 mL 10 mM dNTP mix, 1 mL
0.1 M DTT, 1 mL RNase inhibitor (Enzymatics), and 1 mL
SuperScript III RT (Invitrogen). This mix was added to the
reaction and incubated at 25uC for 10 min, 35uC for 5 min, 55uC
for 45 min, and 85uC for 5 min. RNA/DNA hybrid was removed
by adding 4 mL E. coli RNase H (Enzymatics). PCR reactions
were assembled using 13.75 mL water, 5 mL cDNA, 5 mL5 6HF
buffer, 0.5 mL 10 mM dNTP, 0.25 mL of each 100 mM primer
stock, and 0.25 mL Phusion Hot Start. The reaction was cycled at
98uC (60 s), 24 cycles of 98uC (10 s), 62uC (20 s), and 72uC (20 s),
with a final extension at 72uC (5 min). Samples were purified on a
QIAquick column and run on a 2% agarose E-gel. The desired
bands were purified using the Qiagen MinElute gel extraction kit,
eluted twice with 10 mL EB buffer, and quantitated on a 2100
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which was performed per manufacturer’s instructions.
Pseudovirus production and neutralization assays
To produce pseudoviruses, plasmids encoding Env were co-
transfected with an Env-deficient genomic backbone plasmid
(pSG3DEnv) in a 1:2 ratio with the transfection reagent Fugene 6
(Promega). Pseudoviruses were harvested 72 hours post transfec-
tion for use in neutralization assays. Neutralizing activity was
assessed using a single round of replication pseudovirus assay and
TZM-bl target cells, as described previously [5].
Cell sorting and RNA extraction
Frozen vials of 10610
6 PBMCs were thawed and washed before
staining with Pacific Blue labeled anti-CD3 (UCHT1), Pacific Blue
labeled anti-CD14 (M5E2), FITC labeled anti-CD19 (HIB19), PE-
Cy5 labeled anti-CD10 (HI10a), PE labeled anti-CD27 (M-T271),
and APC labeled anti-CD21 (B-ly4), all from BD Biosciences.
Sorts were performed on a high speed BD FACSAria into
miRVana lysis buffer (Ambion). Immature B cells, exhausted
tissue-like memory, activated mature B cells, resting memory B
cells, and short-lived peripheral plasmablasts were stained using
previously described markers [47]. Total RNA from the cells was
then extracted using the mirVana RNA extraction kit (Ambion)
according to manufacturer’s instructions and quantitated on a
2100 Bioanalyzer (Agilent).
Antibody and protein expression and purification
Antibody sequences were synthesized and cloned into previously
described heavy and light chain vectors [3,48]. The plasmids were
co-transfected (1:1 ratio) in either HEK 293T or 293 FreeStyle
cells using Fugene 6 (Promega) or 293fectin (Invitrogen),
respectively. Transfections were performed according to the
manufacturer’s protocol and antibody supernatants were harvest-
ed four days following transfection. Antibodies produced in 293T
cells were quantified by ELISA and used directly in neutralization
assays. Antibodies produced in 293 freestyle cells were further
purified over a protein A column. Mutations were introduced by
site-directed mutagenesis using the QuikChange site-directed
mutagenesis kit (Stratagene). Recombinant gp120 proteins were
transfected in 293 FreeStyle cells using 293fection (Invitrogen) and
purified with Galanthus nivalis lectin column followed by size
exclusion using Superdex 300 26/60 (GE Healthcare).
Cell surface binding assays
Titrating amounts of mAbs were added to HIV-1 Env-
transfected 293T cells and incubated for 1 h at 4uCi n1 6 PBS.
Following washing, cells were fixed with 2% PFA (PolySciences)
for 20 min at RT. The cells were then washed and stained with a
1:200 dilution of phycoerythrin-conjugated goat anti-human IgG
F(ab9)2 (Jackson) for 1 h at RT. Binding was analyzed using flow
cytometry. Binding competitions were performed by titrating
amounts of competitor monoclonal antibodies before adding
biotinylated antibody at a concentration required to give IC70 and
then measuring binding with phycoerythrin-labeled streptavidin
(Invitrogen). FlowJo software was used for data interpretation.
ELISA assays
Binding by ELISA was performed as described previously [5].
Briefly, plates were coated with goat anti-human IgG Fc (Pierce) or
with gp120 and binding was detected using goat anti-human IgG
F(ab9)2 conjugated to alkaline phosphatase (Pierce). For binding to
gp120 extracted from lysed virions, plates were coated with 5 ng/
uL of sheep D7324 anti-gp120 antibody (Aalto Bio reagents).
Virus supernatents were lysed using a final concentration of 1%
NP-40 and incubated on coated plates for 2 h at 37uC. Detection
was measured using goat anti-human IgG F(ab9)2 conjugated to
alkaline phosphatase (Pierce). Antibody concentration was calcu-
lated by linear regression using a standard concentration curve of
purified IgG protein.
PGT121 germline Fab expression, purification,
crystallization and X-ray diffraction analysis
PGT121germline Fab was produced in HEK 293T cells and
purified as previously described [7]. Briefly, three days after
transfection with the heavy and light chain genes, the expression
media was harvested and the secreted Fab was purified via an anti-
human l light chain affinity matrix (CaptureSelect Fab l; BAC),
followed by cation exchange chromatography and size-exclusion
chromatography. X-ray diffraction quality crystals were obtained in
a condition containing 0.2 M magnesium acetate, 20% w/v PEG
8000, 0.1 M sodium cacodylate, pH 6.5.Before mounting and flash
freezing the crystals in liquid nitrogen, the mother liquor was
supplemented with 20% glycerol for cryo-protection. A complete
datasetwas collected at the APS 23-ID beamline. Data processing
was performed using XDS [49]. The PGT121germline structure
was solved using PHASER in space groups P212121 with the
PGT123 Fab structure as a search model [50]. Refinement was
performed using a combination of PHENIX and COOT [51,52].
Refinement statistics for the final models are reported in Table S1.
Raw data processing: VDJ alignment and clone definition
Raw sequencing data were processed using in-house tools
written in python. Reads were split into barcodes, size-filtered, and
aligned to IMGT’s germline VDJ reference database. The scores
were kept low, as we were interested in sequences that were very
highly mutated. The V region is aligned first, then removed,
followed by J, then removed, followed by D. The IMGT-defined
CDR3 sequence of each read was then extracted. The CDR3
sequences were sorted by abundance and clustered with
USEARCH5.1 with the options ‘‘–minlen 0 –global –usersort –
iddef 1 –id 0.9’’. Finally, each CDR3 sequence was aligned to the
‘‘target’’ antibody sequences of PGT121–123 to determine a
‘‘divergence’’ value from these antibodies.
Antibody variant identification and analysis
The divergence-mutation plots are used as a tool to identify
reads that are similar to the known PGT121–123 antibodies.
High-identity clusters of sequences and clusters that are above
background are manually identified and used as input for a
phylogeny inference with Immunitree. Immunitree implements a
Bayesian model of somatic hypermutation of clones, including
probabilistic models of SHM and sequencing error and performs
Markov chain Monte Carlo over the tree structure, birth/death
times of the subclones, birth/death, mutation, and sequencing
error rates, subclone consensus sequences, and assignment of reads
to nodes. The tree structure is also used for multiple computations
and to overlay different information. We estimate the selection
pressure that a given node has experienced using the BASELINe
algorithm. It performs a Bayesian estimation of selection pressure
by comparing the observed number of replacement/silent
mutations in the CDRs/FWRs of the node consensus sequence.
Supporting Information
Figure S1 PGT121–134 heavy chain divergence plots.
Data generated from 454 sequencing were graphed in identity
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PLOS Pathogens | www.plospathogens.org 16 November 2013 | Volume 9 | Issue 11 | e1003754(PGT bNAb) vs. divergence (germline) plots. Each color represents
a unique clone, which was determined using the procedures
outlined in the methods section. Divergence plots were created for
(A) PGT121, (B) PGT122, (C) PGT123, (D) PGT124, (E)
PGT133, and (F) PGT134.
(TIF)
Figure S2 PGT121–134 light chain divergence plots.
Data generated from 454 sequencing were graphed in identity
(PGT bNAb) vs. divergence (germline) plots. Each color represents
a unique clone, which was determined using the procedures
outlined in the methods section. Divergence plots were created for
(A) PGT121, (B) PGT122, (C) PGT123, (D) PGT124, (E)
PGT133, and (F) PGT134.
(TIF)
Figure S3 ImmuniTree without 454 sequencing error
correction. (A) Heavy chain SHM phylogeny inferred by the
ImmuniTree algorithm without correcting for 454 sequencing
errors. (B) Light chain SHM phylogeny inferred by the
ImmuniTree algorithm without correcting for 454 sequencing
errors. Trees were generated using the same set of sequences to
build the trees in Figure 2.
(TIF)
Figure S4 Neutralization score of each pair tested on 6-
virus panel. Each antibody of different heavy and light chain
pairs was produced in 293T cells and tested for neutralization
activity on a cross-clade 6-virus panel. Neutralization score was
calculated using the formula: mean(log10(10/IC50)). Boxes were
colored as follows: score#1.7, yellow; 1.8#score #2.5, orange;
score.2.5, red.
(TIF)
Figure S5 Nodes can be classified as more PGT121-like
or more PGT124-like based on ImmuniTree clustering.
(A) Heavy chain nodes selected for pairing and characterization
are shown divided into PGT121-like or PGT124-like branches
based on ImmuniTree. (B) Light chain nodes selected for pairing
and characterization are shown divided into PGT121-like or
PGT124-like branches based on ImmuniTree.
(TIF)
Figure S6 Comparison of neutralization profile between
PGT121 and PGT124. PGT121 and PGT124 were tested on 87
cross-clade isolates to determine neutralization breadth and
potency. Listed in colored boxes are IC50 values (mg/ml) of each
isolate neutralized.
(TIF)
Figure S7 Inferred intermediates of PGT121 were
evaluated for neutralization breadth and potency. Heavy
and light chain nodes leading to mAb PGT121 were paired and
tested on a 74-virus panel of PGT121-sensitive viruses. Listed in
colored boxes are IC50 values (mg/ml) of each isolate neutralized.
(TIF)
Figure S8 Inferred intermediates of PGT124 were
evaluated for neutralization breadth and potency. Heavy
and light chain nodes leading to mAb PGT124 were paired and
tested on a 74-virus panel of PGT124-sensitive viruses. Listed in
colored boxes are IC50 values (mg/ml) of each isolate neutralized.
(TIF)
Figure S9 Neutralization table summary of putative
intermediates in comparison to b12. Putative intermediates
3H+3L and 32H+3L were tested in comparision to PGT121 and
b12 in TZM-bl neutralization assays on a cross-clade 103
pseudovirus panel. Listed in colored boxes are percentages of
each clade neutralized. Boxes are colored as follows: percent of
viruses neutralized ,25% (green), percent of viruses neutralized:
25–50% (yellow), percent of viruses neutralized: 50–100 90% (red).
aMutation frequency was calculated over the V-gene and J-gene as
nucleotides (nt) or amino acids (aa) differing from the putative
germline sequence. The CDR3 regions and insertions and
deletions were excluded from the analysis.
(TIF)
Figure S10 Neutralization panel of putative intermedi-
ates in comparison to b12. Inferred intermediates 3H+3L,
and 32H+3L were tested in comparision to PGT121 and b12 in
TZM-bl neutralization assays on a cross-clade 103 pseudovirus
panel. Listed IC50 values are in ug/mL.
(TIF)
Figure S11 Alignment of intermediate and mature
antibodies to germline. Genomic DNA from the PGT121–
123 donor was extracted from CD4+ T cells, which were enriched
through anti-CD4 antibody coated magnetic beads. (A) Primers
designed to amplify the IGHV4-59 and the IGHJ6*03 gene
families were used to generate heavy chain libraries. (B) Primers
designed to amplify the IGLV3-21 and IGLJ3*02 gene families
were used to produce light chain libraries. Both libraries were then
TOPO cloned into vectors and individual colonies were
subsequently Sanger sequenced to determine germline sequences.
Alignments were made using ClustalW.
(TIF)
Figure S12 Paratope mapping of 3H and 3L paired with
heavy and light chains of different maturation levels.
Alanine scanning mutagenesis of heavy chain 3H paired with less-
mutated light chain 3L and highly-mutated light chain 87L as well
as alanine scanning mutagenesis of 3L paired with less-mutated
3H, moderately-mutated 32H, and highly-mutated PGT121H.
Values represent fold-changes in IC50 using formula: Mutan-
t(IC50)/WT(IC50). Empty gray boxes represent isolates for which
the antibody did not neutralize
(TIF)
Figure S13 Reversion of all residues in 3H except
CDRH3 results in loss of neutralization for 20% of
isolates. Alanine scanning mutagenesis of heavy chain 3H paired
with 3L were tested in TZM-bl neutralization assays on viruses
previously determined to be neutralized by 3H+3L. Listed IC50
values are in ug/mL.
(TIF)
Figure S14 Many of the residues from SHM may play a
role in stabilizing antibody structure and conformation.
Structural representation of the mutations that occurred in
PGT123 during affinity maturation from a putative germline
antibody. Residues thought to have mutated are shown in blue
and red for the light and heavy chains, respectively. Mutations are
seen to have taken place across all regions of the Fv domain and
contribute to both paratope evolution and antibody architecture.
(TIF)
Figure S15 Single and double mutant summary of
inferred intermediate antibodies 3H+87L to 3H+3L and
32H+3L to 3H+3L. Reversion of single and double residues of
light chain 87L to light chain 3L and paired with heavy chain 3H.
WT and reverted mutants were tested on isolate (A)
1006_11_C3_1601 and (B) SC422661.8. (C) Reversion of single
and double residues of heavy chain 32H to heavy chain 3H and
paired with light chain 3L. WT and reverted mutants were tested
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formula Mutant(IC50)/WT(IC50). ND represent double mutants
that were not determined.
(TIF)
Figure S16 The least mutated antibody variant 3H+3L
binds recombinant gp120 less well than the affinity
mature PGT121. Recombinant gp120s were produced in 293F
cells and purified by lectin column before use in ELISA binding
assays. ELISA values are reported in optical density at 405 nm
(OD405).
(TIF)
Figure S17 Illustration of role of somatic hypermuta-
tion in the development of neutralization breadth.
Models for development of neutralization breadth via SHM by
targeting the ‘‘sweet spot’’ on HIV Env. Breadth can either
develop by converging onto or by reorienting onto a highly
conserved region on HIV Env as illustrated. This convergence or
reorientation is directed by virus escape mutations, which select for
antibodies that interact with conserved regions (glycans, conserved
side chains and main chain atoms) and less dependency on
variable residues (variable side chains). By this process, affinity
selection can lead to greater neutralization breadth and potency.
(TIF)
Figure S18 In silico experiments show that bNAbs form
stronger contacts with conserved sites than with vari-
able sites on Env. Each bNAb is represented by a pair of points,
one red point and one blue point. The red point represents the
average interaction strength of residues on the bNAb with variable
sites of the antigen, and the blue point represents the average
interaction strength with conserved antigen sites. The 63 red and
blue points shown correspond to the 63 bNAbs that emerged in
silico. The purple bars indicate the mean value averaged over all
the selected antibodies. A significant difference between the mean
values (purple bars) is apparent (P,0.001).
(TIF)
Figure S19 A draw from the generative model of a
synthetic clone producing 1000 reads. Each node is a cell.
The size of a cell is proportional to the number of reads it produced
(with noise). which is also listed next to it. Each edge is a birth event
and next to it is listed the mutation distance between parent and
child. Cells with identical sequences are marked with same color.
(TIF)
Figure S20 A binary tree by FastTree 2.0. A binary tree
was generated using 1000 synthetic reads of Figure S19 and
visualized using Archeopteryx.
(TIF)
Figure S21 Mutation trees for the synthetic clone are
obtained by collapsing edges marked with 0. (A) The true
mutation tree for Figure S1. For tracking purposes, we color the
reads of each cell by the cell’s color. (B) The mutation tree
returned by running ImmuniTree on the 1000 synthetic reads.
Each cell is a pie chart showing the color composition of its reads.
Almost each node in the reconstructed tree retained its identity,
and the trees have an almost identical topology.
(TIF)
Figure S22 Comparison of the average missing-branch
(k) rate for different values of k between FastTree and
ImmuniTree over 100 synthetic clones. Comparison of the
average missing-branch(k) rate, for different values of k, between
FastTree and ImmuniTree, over 100 synthetic clones. From each
synthetic clone we simulated 1000 reads, and let ImmuniTree and
two other tree construction methods (FastTree and MrBayes)
reconstruct the true tree that generated those reads. Each tree
branchinduces a partitionof the reads into two sets (based on which
side of the branch they are at). For each branch of the true tree we
found the branch in the reconstructed tree with the minimum
number of reads that need to switch sides in order for the induced
partitions to match. Missing-branch(k) is the fraction of branches in
the true tree for which the above minimum was greater than k.
(TIF)
Figure S23 An illustration of the generative model. First,
a tree of cells is generated, each cell has a parent cell, a birth time
and a death time. Then, the sequences of these cells are filled in
from top to bottom, each sequence is a copy of its parent, with a
slight chance of mutation. Last, reads are generated from the cells
alive at the end of the process, with added sequencing noise.
(TIF)
Figure S24 A subgraph of an internal node. Each
horizontal line is a cell. Let the top cell be called R. v is a birth
event in R’s life, and nodes u and w are the previous and next
events (we assume here they are both birth events). The nodes f, e,
b, c represent the next event in each cell’s life, either birth or
death. Similarly, the node a represents the event preceding u on
R’s life, which could be either another birth or R’s own birth. One
of our MCMC moves proposes to disconnect the edge vRc from
the tree, and reconnect it to a new position on this subgraph.
(TIF)
Figure S25 Comparison between binary tree and output
from ImmuniTree. (A) A binary tree sampled from the
algorithm. Horizontal lines represent lifetimes of cells. Vertical
lines represent birth events. Numbers indicate the mutation
distance between the child and its parent (0 if not indicated). Cells
with identical sequences are marked by the same color. (B) The
reported canonical tree after collapsing identical sequences to a
single node (of matching color). Number inside the nodes indicate
the number of reads associated with that node.
(TIF)
Table S1 X-ray crystallography statistics of
PGT121germline.
(TIF)
Text S1 Supplementary text describing ImmuniTree.
Description of a novel Bayesian method called ImmuniTree,
which models antibody somatic hypermutation while accounting
for sequencing error. Supplementary text includes in silico
experiments and additional details on how the algorithm was
designed.
(PDF)
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